• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

Document Explains Decision Granting Sovaldi Patent To Gilead

10/05/2016 by Patralekha Chatterjee for Intellectual Property Watch Leave a Comment

A copy of the new Indian patent office order shows the details of the decision to reverse an earlier direction and grant a patent in India on the high-value hepatitis C drug. [Updated with response from Gilead]

Filed Under: IP Policies, Language, Subscribers, Themes, Venues, Asia/Pacific, English, Health & IP, IP Law, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy

Infojustice.org – Australian Commission Recommends Fair Use To Restore Balance In Copyright Law

03/05/2016 by Intellectual Property Watch 1 Comment

Infojustice.org reports: A draft report by the Australian Productivity Commission (APC) concludes that the current copyright law fails to properly balance the interests of copyright holders and users. It warns that “Australia’s copyright arrangements are weighed too heavily in favour of copyright owners, to the detriment of the long-term interests of both consumers and intermediate users.” The APC makes recommends changes to the law to address the imbalance, including “the introduction of a broad, principles-based fair use exception.”

Filed Under: IP-Watch Briefs, IP Policies, Themes, Venues, Access to Knowledge/ Education, Asia/Pacific, Copyright Policy, Information and Communications Technology/ Broadcasting, Outside Sources, Regional Policy

Special Report: The Battle For Biosimilars In India

02/05/2016 by Patralekha Chatterjee for Intellectual Property Watch 1 Comment

[story updated] Biosimilar drugs hold out big opportunities for India’s drug companies. But the future is fraught with challenges. One key challenge is regulations.

What does this mean for countries like India, an emerging market for biosimilars? How will the evolving global regulatory environment on biosimilars impact patients?

Last month, both these questions came to the fore as the battle over biosimilars moved centre stage in this country in the wake of an interim order by the Delhi High Court, and then another decision by a Division Bench of the same court which took a different view.

Filed Under: Features, IP Policies, Language, Subscribers, Themes, Venues, Asia/Pacific, Biodiversity/Genetic Resources/Biotech, English, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy

Leaked IP Chapter Of Asian FTA Reveals Tough Rules For Poorer Partners, Civil Society Says

20/04/2016 by Catherine Saez, Intellectual Property Watch 2 Comments

The alleged intellectual property chapter of a secretive regional trade agreement between an association of ten Asian countries plus six others was released yesterday by a civil society group, which says richer countries in the region are pushing for stringent IP rules.

Filed Under: IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Asia/Pacific, Bilateral/Regional Negotiations, Enforcement, English, Health & IP, Human Rights, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer

US Tech Industry Associations Endorse TPP

31/03/2016 by Intellectual Property Watch 2 Comments

A number of internet and software industry in the United States have come out in support of the Trans-Pacific Partnership (TPP) negotiated by the Office of the US Trade Representative (USTR) last year.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Asia/Pacific, Bilateral/Regional Negotiations, Copyright Policy, English, Innovation/ R&D, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy, Trademarks/Geographical Indications/Domains

India, EU Leaders Touch On IPR, Innovation, ICTs, Pharmaceuticals

30/03/2016 by Intellectual Property Watch 1 Comment

The leaders of India and the European Council today in Brussels discussed a wide range of topics including intellectual property rights – including geographical indications – innovation, digital issues, and health and pharmaceuticals.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Asia/Pacific, Bilateral/Regional Negotiations, Copyright Policy, English, Europe, Health & IP, Information and Communications Technology/ Broadcasting, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy, Trademarks/Geographical Indications/Domains

Special Report: India Rocked By Report Of Secret Assurance To US Industry On IP

22/03/2016 by Patralekha Chatterjee for Intellectual Property Watch 2 Comments

That the Indian government has been under pressure from the United States to change its patent regime is no secret among those who follow the public discourse on intellectual property rights. Now, a new controversy about India’s alleged private assurance to the US-India Business Council (USIBC) and other lobby groups that it would not invoke compulsory licensing for commercial purposes seeks to add fuel to fiery speculation about a shift in India’s policy on IPR.

Filed Under: Features, IP Policies, Language, Themes, Venues, Access to Knowledge/ Education, Asia/Pacific, Bilateral/Regional Negotiations, Enforcement, English, Health & IP, Innovation/ R&D, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy, WTO/TRIPS

Asian Voices On Access to Medicines: Scrap TRIPS, Voluntary Licences Not Working, FTA Threats

18/03/2016 by Catherine Saez, Intellectual Property Watch 2 Comments

Speakers from Asian civil society provided recommendations to the public hearing of the United Nations Secretary General’s High-Level Panel on Access to Medicines held yesterday. They underlined the unaffordability of medicines in their countries, the inefficiency of current mechanisms such as voluntary licensing, and the pressure applied by pharmaceutical companies and the United States and Europe to prevent the use of compulsory licences. One speaker warned against the expert advice given by the World Intellectual Property Organization to least-developed countries, while others pointed to stringent intellectual property measures in free-trade agreements.

Filed Under: IP Policies, Language, Themes, Venues, Asia/Pacific, English, Health & IP, Human Rights, Innovation/ R&D, Lobbying, Patents/Designs/Trade Secrets, Regional Policy, Technical Cooperation/ Technology Transfer, United Nations - other

US Officials Under Pressure To Include Industry In IP Talks With India

16/03/2016 by Intellectual Property Watch 2 Comments

The United States government has increasingly engaged India on intellectual property rights and other trade issues in recent years, and US negotiators are under still more pressure to include industry in this engagement and deliver more results, a recent letter from 14 members of the US Congress shows.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, Asia/Pacific, Copyright Policy, Enforcement, English, Lobbying, North America, Patents/Designs/Trade Secrets, Regional Policy, Trademarks/Geographical Indications/Domains

China’s Pharmaceutical Sector And The IP Puzzle

15/03/2016 by Intellectual Property Watch Leave a Comment

Despite impressive growth, the pharmaceutical sector in China still relies on generic drug production since the majority of domestic companies cannot compete with country-based foreign corporations. Currently, following WTO pressure to oblige China to comply with IP regulations, more and more patented drugs are entering the market. Unfortunately, in spite of a newly introduced IP friendly bill, a puzzling situation persists, writes Pietro Dionisio.

Filed Under: Features, Inside Views, IP Policies, Language, Themes, Venues, Asia/Pacific, Enforcement, English, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, Regional Policy

  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 43
  • Next Page »
  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2026 · Global Policy Reporting